Replies to post #132197 on $Pistol Pete$, $Mick$ & Friends Stock Picks /news,

[$Pistol Pete$]

$PMCB Pharmacyte Biotech Inc (OTCMKTS:PMCB) reported that its senior management will attend the annual meeting of the ASCO. The theme of this meeting is focused on bringing a difference in cancer care. Kenneth L. Waggoner, the CEO, reported that this year’s yearly meeting of ASCO will be most significant as they work towards registering the first patient in their planned clinical study in locally advanced pancreas cancer.

https://www.mmjobserver.com/pharmacyte-biotech-inc-otcmktspmcb-to-attend-asco-annual-meeting/28755/

[$Pistol Pete$]

Hey MICK

I will be travel oversea tonight and won't be back until July 15. I will be slow on the response

[$Pistol Pete$]

$WFM Amazon, Whole Foods Deal Is A Big Win For Consumers

https://www.forbes.com/sites/hbsworkingknowledge/2017/06/17/amazon-whole-foods-deal-is-a-big-win-for-consumers/
Amazon, Whole Foods Deal Is A Big Win For Consumers

Forbes - 7h ago


Editor's Note: Online retailing behemoth Amazon announced yesterday that it would acquire upscale grocery chain Whole Foods Market in a deal valued at more than $13 billion. Though the company has dabbled with the idea of a brick-and-mortar footprint ...

[$Pistol Pete$]

$WFM Whole Foods Market, Inc. (WFM) Ex-Dividend Date Scheduled for June 28, 2017 WFM

http://www.nasdaq.com/article/whole-foods-market-inc-wfm-ex-dividend-date-scheduled-for-june-28-2017-cm808563

[$Pistol Pete$]

$SPOM http://baxternewsreview.com/a-chartists-perspective-on-spo-global-inc-spom/97946/
A Chartists Perspective on SPO Global Inc (SPOM)
Baxter Review - 21h ago


Traders may be trying to figure out whether it is a good time to enter or exit a position in SPO Global Inc (SPOM). The Average Directional Index or ADX is a technical analysis indicator used to describe if a market is trending or not trending.

[$Pistol Pete$]

$AZFL getting hot since I called it at $.0001 my Friend

[$Pistol Pete$]

$DCAC http://aikenadvocate.com/daniels-corporate-advisory-company-inc-dcac-ichimoku-levels-in-focus/337634/
Daniels Corporate Advisory Company Inc (DCAC): Ichimoku Levels in Focus
Aiken Advocate - 6h ago


Shares of Daniels Corporate Advisory Company Inc (DCAC) opened the last session at $0.0002, touching a high of $0.0003 and a low of $0.0001 , yielding a change of -0.0001.

[mick]

i was in pain today, back, etc traction. only aspirin fer relief.

[mick]

interesting weather, we pray for all and for safety. IRMA is very active.

[mick]

From Our Friends/ 09-12-2017

http://investorshub.advfn.com/STOCKGOODIES-PLAYS-OF-THE-WEEK-18582/

What is an IPO? BoomPickens 09/12/17 05:59:44 AM
#2659096 Daily Candlestick Chart for TFONF GreenReeper 09/12/17 05:59:40 AM
#2659095 Appreciation: An increase in value of currency due Tellin_Fibs 09/12/17 05:59:20 AM
#2659094 Narrow Within the Group BoomPickens 09/12/17 05:59:06 AM
#2659093 Daily Candlestick Chart for ATDM GreenReeper 09/12/17 05:58:47 AM
#2659092 Delivery Date: The date of maturity of a Tellin_Fibs 09/12/17 05:58:44 AM
#2659091 Will somebody always buy my stocks when I BoomPickens 09/12/17 05:58:22 AM
#2659090 Daily Candlestick Chart for PSID GreenReeper 09/12/17 05:58:11 AM
#2659089 Double Bottom: A Double Bottom is a form Tellin_Fibs 09/12/17 05:58:07 AM
#2659088 Sometimes, there is a price cluster with a BoomPickens 09/12/17 05:57:45 AM
#2659087 Daily Candlestick Chart for TUCN GreenReeper 09/12/17 05:57:22 AM

Analyst: When analyzing the market, analysts can generally Tellin_Fibs 09/12/17 05:57:19 AM
#2659085 What is day trading? BoomPickens 09/12/17 05:57:11 AM
#2659084 Daily Candlestick Chart for ROSV GreenReeper 09/12/17 05:56:45 AM
#2659083 Bank of Japan (BOJ) Monetary Policy Monthly Report: Tellin_Fibs 09/12/17 05:56:41 AM
#2659082 Two Dominant Groups BoomPickens 09/12/17 05:56:19 AM
#2659081 Daily Candlestick Chart for AEMD GreenReeper 09/12/17 05:56:13 AM
#2659080 Drawdown: Drawdown is a measure of peak-to-trough decline, Tellin_Fibs 09/12/17 05:56:10 AM
#2659079 What is the Big Board? BoomPickens 09/12/17 05:55:43 AM
#2659078 Daily Candlestick Chart for HYSR GreenReeper 09/12/17 05:55:41 AM
#2659077 Ascending Trend Line: A bullish pattern created by Tellin_Fibs 09/12/17 05:55:17 AM

===================================================


This link will help thou $GIHI BarChart Technical Black_NITE 09/12/17 07:59:51 AM
#754294 Index Mutual Funds Vs. Index ETFs GreenReeper 09/12/17 07:59:45 AM
#754293 FINRA requires member firms to ascertain the best Tellin_Fibs 09/12/17 07:59:42 AM
#754292 The choice of data compression and time frame BoomPickens 09/12/17 07:59:40 AM
#754291 This link will help thou $GMXS BarChart Technical Black_NITE 09/12/17 07:59:15 AM
#754290 3 Questions To Find Your Trading Plan GreenReeper 09/12/17 07:59:10 AM
#754289 When the stock failed to advance past 42.5, BoomPickens 09/12/17 07:58:51 AM
#754288 There is a public interest concern associated with Tellin_Fibs 09/12/17 07:58:50 AM
#754287 $LYJN BarChart Technical Analysis NITE-LYNX http://www.barchart.com/technicals/s Black_NITE 09/12/17 07:58:41 AM
#754286 The Basics Of Outstanding Shares And The Float GreenReeper 09/12/17 07:58:19 AM
#754285 Priced quotations in the OTC Link or the Tellin_Fibs 09/12/17 07:58:17 AM
#754284 Key points on the benefits of arithmetic and BoomPickens 09/12/17 07:58:17 AM
#754283 $INKPQ BarChart Technical Analysis NITE-LYNX http://www.barchart.com/technicals/ Black_NITE 09/12/17 07:57:52 AM
#754282 4 Traits Of A Great Index Fund GreenReeper 09/12/17 07:57:44 AM
#754281 The chart below shows that relative performance of BoomPickens 09/12/17 07:57:41 AM
#754280 Companies create and sell securities in the market Tellin_Fibs 09/12/17 07:57:40 AM
#754279 Behold the $TFER BarChart Technical Analysis NITE-LYNX Black_NITE 09/12/17 07:57:15 AM
#754278 Digging Deeper Into Bull And Bear Markets GreenReeper 09/12/17 07:57:09 AM
#754277 OTC Markets has determined that there is a Tellin_Fibs 09/12/17 07:56:47 AM
#754276 Supply, Demand, and Price Action BoomPickens 09/12/17 07:56:46 AM
#754275 $CYUXF BarChart Technical Analysis NITE-LYNX http://www.barchart.com/technicals/ Black_NITE 09/12/17 07:56:41 AM
#754274 5 ETFs Flaws You Shouldnt Overlook GreenReeper 09/12/17 07:56:20 AM
#754273 Many economists link economic expansion and contraction to BoomPickens 09/12/17 07:56:12 AM
#754272 Many foreign issuers adhere to the listing requirements Tellin_Fibs 09/12/17 07:56:11 AM
#754271 This link will help thou $ATCN BarChart Technical Black_NITE 09/12/17 07:55:46 AM
#754270 Portfolio Mismanagement: 7 Common Stock Errors GreenReeper 09/12/17 07:55:43 AM
#754269 Traders usually concentrate on charts made up of BoomPickens 09/12/17 07:55:19 AM
#754268 The Financial Industry Regulatory Authority (FINRA) and the Tellin_Fibs 09/12/17 07:55:18 AM
#754267 BarChart Technical Analysis NITE-LYNX $FRGY Black_NITE 09/12/17 07:55:14 AM

http://investorshub.advfn.com/Sizzling-Stock-Picks-17227/

[$Pistol Pete$]

How are you today?

[mick]

Stock Market News
Detroit Rolls Ahead On Electric Vehicles -- WSJ

[mick]

$DIS, is old news that did not happen/

[beambe]

BONT-$$$

[mick]

https://investorshub.advfn.com/Global-Techs-Ltd-GTLL-11221/

[mick]

https://www.barchart.com/stocks/quotes/BMGP/cheat-sheet

[mick]

$KERMF Gold Alert

[mick]

Stock Market News
Serica Energy Buys Three North Sea Oil Field Interests From BP; Names New CEO

[mick]

good morning, $ETST

[$Pistol Pete$]

$PMCB Gold Standard Cell-In-The-Box Technology: Pharmacyte Biotech Inc (OTCMKTS:PMCB)

http://www.microcapdaily.com/gold-standard-cell-in-the-box-technology-pharmacyte-biotech-inc-otcmktspmcb/120034/

[$Pistol Pete$]

$PMCB Daily and Weekly Chart

[$Pistol Pete$]

$MCGI https://thestocktalker.com/market-focus-shares-pushing-higher-50-00-over-the-last-month-medcareers-group-in-mcgi/Market Focus: Shares Pushing Higher 50.00% Over the Last Month: Medcareers Group In (MCGI)
Stock Talker - 4h ago


Zooming in on shares of Medcareers Group In (MCGI) we have seen that the stock price has gained 50.00% over the last 4-weeks.Market Focus: Shares Pushing Higher 50.00% Over the Last Month: Medcareers Group In (MCGI)
Stock Talker - 4h ago


Zooming in on shares of Medcareers Group In (MCGI) we have seen that the stock price has gained 50.00% over the last 4-weeks.

[$Pistol Pete$]

$LVGI https://searcysentinel.com/what-are-the-technical-charts-saying-about-limitless-venture-group-inc-lvgi/426669/What are the Technical Charts Saying About Limitless Venture Group Inc (LVGI)?
Searcy News - 23h ago


Investors and traders using technical analysis to examine stocks may be interested in taking a look at the ATR or Average True Range.What are the Technical Charts Saying About Limitless Venture Group Inc (LVGI)?
Searcy News - 23h ago


Investors and traders using technical analysis to examine stocks may be interested in taking a look at the ATR or Average True Range.

[$Pistol Pete$]

$ZMRK https://finnewsweek.com/zalemark-holding-co-zmrk-ichimoku-reveals-negative-momentum/704782/Zalemark Holding Co (ZMRK) Ichimoku Reveals Negative Momentum
Financial Newsweek - Jan 6, 2018


Zalemark Holding Co (ZMRK) shares opened the last session at 0.0010, touching a high of 0.0012 and a low of 0.0010 , yielding a change of 0.0003.Zalemark Holding Co (ZMRK) Ichimoku Reveals Negative Momentum
Financial Newsweek - Jan 6, 2018


Zalemark Holding Co (ZMRK) shares opened the last session at 0.0010, touching a high of 0.0012 and a low of 0.0010 , yielding a change of 0.0003.

[$Pistol Pete$]

$MTVX https://clawsonnews.com/performance-focus-apt-moto-vox-group-inc-mtvx-shares-higher-9900-00-over-the-past-month/Performance Focus: Apt Moto Vox Group Inc (MTVX) Shares Higher 9900.00% Over the Past Month
Clawson News - 3h ago


Investors tracking shares of Apt Moto Vox Group Inc (MTVX) may have taken notice that the stock has risen 9900.00% over the last 4 weeks.Performance Focus: Apt Moto Vox Group Inc (MTVX) Shares Higher 9900.00% Over the Past Month
Clawson News - 3h ago


Investors tracking shares of Apt Moto Vox Group Inc (MTVX) may have taken notice that the stock has risen 9900.00% over the last 4 weeks.

[$Pistol Pete$]

$LVGI $.0004 is cleared

[$Pistol Pete$]

$LVGI Barchart Opinion 64% "BUY" LVGI

https://www.barchart.com/stocks/quotes/lvgi/opinion

[$Pistol Pete$]

Happy Birthday MICK!!!! All the best to you my Friend

[$Pistol Pete$]

GM MICK and Everyone

[mick]

thank you for heads up $VDRM

[mick]

Flexible Solutions International Inc. (NYSE: FSI), an environmental technology company involved in products that increase crop yield, improve oil and gas operations, reduce the environmental footprint in cleaning and water treatment, to save water and save energy.

[mick]

[$Pistol Pete$]

$DFFN on the breakout mode

[mick]

GSRX Expands Retail Cannabis Sales Into California

Green Spirit Industries (OTC: GSRX) announced a deal to acquire an established dispensary operation in Point Arena, a popular coastal town in Northern California's Mendocino County. Recreational cannabis sales in the state began in January and should provide a strong boost to revenue in the quarters ahead.

[$Pistol Pete$]

$LVGI We have completed a successful third quarter! HempCore products are available on our Ascend Global MLM website, although not part of the Gold or Platinum packages yet. LVGI has completed its Acquisition of the e-cig and CBD products, working on repackaging. More news to follow. LVGI

We have completed a successful third quarter! HempCore products are available on our Ascend Global MLM website, although not part of the Gold or Platinum packages yet. LVGI has completed its Acquisition of the e-cig and CBD products, working on repackaging. More news to follow.

— Joseph Francella (@joeceolvgi) April 3, 2018

[$Pistol Pete$]

$PMCB good presentation for review PMCB

https://content.equisolve.net/_b845632d9c6284bd5445d5d5145ea2e9/pharmacytebiotech/db/184/417/pdf/Presentation+for+Website+-+Februry+2018.pdf

[$Pistol Pete$]

$PMCB PharmaCyte Biotech Reports Successful Completion of Long-term Studies on Cells Used in Pancreatic Cancer Therapy PMCB



https://www.businesswire.com/news/home/20180430005458/en/PharmaCyte-Biotech-Reports-Successful-Completion-Long-term-Studies

[$Pistol Pete$]

I will be travel oversea on Tues and won’t be back for 2 weeks. I will try to be online as much as I can though. Hope your Wife is getting better now

[insymbols]

$$$$$ $BRGO $$$$$ Red Hot!

[$Pistol Pete$]

$MNKD H.C. Wainwright Sticks with the Bulls on MannKind (MNKD), But Lowers Price Target on Sluggish Afrezza Adoption. Target is $5 MNKD

https://www.smarteranalyst.com/analyst-insights/h-c-wainwright-sticks-bulls-mannkind-mnkd-lowers-price-target-sluggish-afrezza-adoption/

[$Pistol Pete$]

$MNKD very good news

https://seekingalpha.com/instablog/49502855-m4ngo/5169062-mannkind-afrezza-blooming-scientific-chatter

[$Pistol Pete$]

$MNKD Daily and Weekly Charts

[$Pistol Pete$]

$RAD Daily and Weekly Charts

[$Pistol Pete$]

$PMCB Daily and Weekly Charts

[$Pistol Pete$]

$PMCB Daily and Weekly Chart

[$Pistol Pete$]

$MNKD One Small Step For Technosphere, One Giant Leap For MannKind MNKD

https://seekingalpha.com/instablog/19708111-kastanes/5171051-one-small-step-technosphere-one-giant-leap-mannkind

[$Pistol Pete$]

$PMCB Barchart Opinion 80% “BUY"

https://www.barchart.com/stocks/quotes/PMCB/opinion




Go $PMCB

[$Pistol Pete$]

F.A.M.I.L.Y
is one of the sweetest word
Anyone can say,
Because
The letters of FAMILY means…
“Father and Mother I Love You.. !!”

Happy Father’s Day Everyone

[$Pistol Pete$]

$MNKD MannKind Presents Positive Afrezza® Clinical Data from STAT and AFFINITY Studies at ADA 78th Scientific Sessions

http://www.globenewswire.com/news-release/2018/06/23/1528571/0/en/MannKind-Presents-Positive-Afrezza-Clinical-Data-from-STAT-and-AFFINITY-Studies-at-ADA-78th-Scientific-Sessions.html

[$Pistol Pete$]

$AAPL Thank you Mr. President to bring job to Wisconsin

https://mashable.com/2018/06/29/apple-foxconn-iphone-factory.amp/

[$Pistol Pete$]

$GE General Electric wins $437 mln U.S. defense contract

https://m.nasdaq.com/article/general-electric-wins-437-mln-us-defense-contract-20180629-00893

[$Pistol Pete$]

Happy 4th of July to you and Everyone on this board. May God Bless Us and Bless America

[$Pistol Pete$]

$MU this is a big joke from China

Micron to Challenge Chinese Court Ruling Over Alleged Patent Infringement

Source: Dow Jones News
By Austen Hufford
Micron Technology Inc., America's largest memory-chip maker, is challenging a Chinese court decision that temporarily halted the sale of some of its products in the country.

Micron said Thursday that a Chinese court in the Fujian Province temporarily stopped the sale of certain Crucial and Ballistix-branded memory modules and solid state drives, which make up slightly more than 1% of the company's total annual revenue.

Micron said it would comply with the ruling while also asking the court to reconsider or stay its decision. The company expects its revenue for the current quarter to be within its previously guided range of $8 billion to $8.4 billion.

Shares rose nearly 2% in early trading Thursday. Shares fell 5.5% Tuesday after the injunction and didn't trade on Wednesday due to the Fourth of July holiday in the U.S.

State-owned chip maker Fujian Jinhua Integrated Circuit Co. and its Taiwanese partner, United Microelectronics Corp., accused Micron in January in China of making products that violate their separate patents. That came a month after the U.S. company filed a lawsuit in California alleging Jinhua and UMC stole Micron's trade secrets at its Taiwan plant. Jinhua has denied the allegations. On Thursday, Micron said Fujian and United Microelectronics filed the lawsuits in "retaliation."

Micron also said the patents are invalid and that its products don't infringe on them.

"The central government of China has often stated that the rights of foreign companies are fairly and equally protected in China," the company said in a statement. "Micron believes the ruling issued by the Fuzhou Court in Fujian Province is inconsistent with this proclaimed policy."

Write to Austen Hufford at [e-mail]


(END) Dow Jones Newswires

July 05, 2018 10:03 ET (14:03 GMT)

Copyright (c) 2018 Dow Jones & Company, Inc.

[$Pistol Pete$]

$MNKD Improved Time-in-Range (TIR) on Continuous Glucose Monitor (CGM) with Technosphere Inhaled Insulin (TI) compared to insulin Aspart in Patients with T1D—STAT Study ADA 2018, poster 1017-P



Total and Severe Hypoglycemia Is Reduced With Use of Inhaled Technosphere® Insulin (AFREZZA®) Relative to Insulin Aspart in Type 1 Diabetes ADA 2018, poster 102-LB



• Source
www.mannkindcorp.com/research-development/publications/

[$Pistol Pete$]

$PMCB PharmaCyte Biotech Successfully Completes Another FDA Required Study Necessary for Submitting Investigational New Drug Application PMCB

https://www.nasdaq.com/press-release/pharmacyte-biotech-successfully-completes-another-fda-required-study-necessary-for-submitting-20180614-00515



Go $PMCB

[$Pistol Pete$]

$TROV Trovagene Receives Positive Opinion for Orphan Drug Designation in the European Union for PCM-075, Trovagene's Investigationa...

Source: PR Newswire (US)
SAN DIEGO, Aug. 1, 2018 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a clinical-stage oncology therapeutics company, developing targeted therapeutics for the treatment of leukemias/lymphomas and solid tumor cancers, today announced that the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) has adopted a positive opinion recommending PCM-075 for designation as an orphan medicinal product for the treatment of Acute Myeloid Leukemia (AML). PCM-075 is a first-in-class, 3rd generation, highly selective, oral Polo Like Kinase 1 (PLK1) inhibitor, that is designed to target cell division (mitosis).

Trovagene is a clinical-stage oncology therapeutics company, developing targeted therapeutics for the treatment of solid tumor cancers and leukemias/lymphomas.

"The positive opinion from the EMAs Committee for Orphan Medicinal Products, based on our in vivo data supporting medical plausibility and the potential for significant benefit of PCM-075, marks another milestone in our efforts to improve the lives of patients suffering from AML," said Dr. Thomas Adams, Chairman and Interim Chief Executive Officer of Trovagene. "We believe that PCM-075, in combination with standard-of-care chemotherapies and targeted therapeutics, has the potential to provide significant clinical benefit with regard to efficacy and safety in patients with AML and we remain keenly focused on advancing our ongoing multi-center Phase 1b/2 clinical trial."

To be considered for Orphan Drug Designation in the EU, companies must provide data that demonstrates plausibility for use of the investigational therapy in the treatment of the disease and establish that the drug has the potential to provide relevant advantages or a major contribution to patient care over existing therapies. The opinion letter sent to Trovagene by the COMP stated that "although satisfactory methods of treatment of the condition have been authorized in the EU, PCM-075 will be of significant benefit to those affected by AML."

The COMP, a committee of the EMA, adopts an opinion on the granting of orphan drug designation, after which the opinion is submitted to the European Commission for endorsement of the opinion. The positive opinion issued by the COMP is anticipated to be adopted by the European Commission (EC) at the end of August 2018.

Orphan drug designation by the European Commission provides regulatory and financial incentives for companies to develop and market therapies to treat a life-threatening or chronically debilitating condition affecting no more than five in 10,000 persons in the European Union (EU), and where no satisfactory treatment is available. Among the incentives available to therapeutics designated as orphan drugs by the EC are ten-year market exclusivity in the EU after product approval, eligibility for conditional marketing authorization, protocol assistance from the EMA at reduced fees during the product development phase and direct access to centralized marketing authorization in the EU.

About Acute Myeloid Leukemia (AML)

Acute myeloid leukemia (AML) is an aggressive hematologic malignancy in which myeloid lineage cells of the bone marrow cease to differentiate appropriately, resulting in a marked increase in the number of circulating immature blast cells. As a consequence, the counts of mature red blood cells, platelets, and normal white blood cells decline, causing fatigue, shortness of breath, bleeding, and increased susceptibility to infection. The incidence is estimated to be approximately 18,000 new cases annually in the EU and is on the rise due to the aging population. The five-year survival rate is approximately 22%.

About PCM-075

PCM-075 is a highly-selective adenosine triphosphate (ATP) competitive inhibitor of the serine/threonine polo-like-kinase 1 (PLK 1) enzyme, which is over-expressed in multiple hematologic and solid tumor cancers. Separate studies with other PLK inhibitors have shown that inhibition of polo-like-kinases can lead to tumor cell death, including a Phase 2 study in Acute Myeloid Leukemia (AML) where response rates up to 31% were observed when used in conjunction with a standard therapy for AML (low-dose cytarabine-LDAC) versus treatment with LDAC alone with a 13.3% response rate. A Phase 1 open-label, dose escalation safety study of PCM-075 has been completed in patients with advanced metastatic solid tumor cancers and published in Investigational New Drugs. The maximum tolerated dose (MTD) or recommended Phase 2 dose (RP2D) in this trial was 24 mg/m2. Trovagene has an ongoing Phase 1b/2 clinical trial with PCM-075 in AML that was accepted by the National Library of Medicine (NLM) and is now publicly viewable on www.clinicaltrials.gov. The NCT number assigned by clinicaltrials.gov for this study is NCT03303339. PCM-075 has been granted Orphan Drug Designation by the FDA for the treatment of patients with AML. Trovagene is enrolling a Phase 2 trial of PCM-075 in combination with Zytiga® (abiraterone acetate) and prednisone in metastatic Castration-Resistant Prostate Cancer that was accepted by the National Library of Medicine (NLM) and is now publicly viewable on www.clnincaltrials.gov. The NCT number assigned by clinicaltrials.gov for this study is NCT03414034.

PCM-075 only targets the PLK1 isoform (not PLK2 or PLK3), is orally available, has a 24-hour drug half-life with reversible on-target hematologic toxicities. Trovagene believes that targeting only PLK1 with reversible on-target activity and an improved dose/scheduling protocol can significantly improve on the long-term outcome observed in previous studies with a PLK inhibitor in AML.

PCM-075 has demonstrated synergy in preclinical studies with over 10 chemotherapeutic and target agents used in hematologic and solid tumor cancers, including FLT3 and HDAC inhibitors, taxanes, and cytotoxins. Trovagene believes the combination of its targeted PLK1 inhibitor, PCM-075, with other compounds has the potential for improved clinical efficacy in Acute Myeloid Leukemia (AML), metastatic Castration-Resistant Prostate Cancer (mCRPC), Non-Hodgkin Lymphoma (NHL), Triple Negative Breast Cancer (TNBC), as well as other hematologic and solid tumor cancers.

About Trovagene, Inc.

Trovagene is a clinical-stage, oncology therapeutics company, using a precision medicine approach to develop drugs that target mitosis (cell division) to treat various types of cancer, including leukemias/lymphomas and solid tumors. Trovagene has intellectual property and proprietary technology that enables the Company to analyze circulating tumor DNA (ctDNA) and clinically actionable markers to identify patients most likely to respond to specific cancer therapies. Trovagene plans to continue to vertically integrate its tumor genomics technology with the development of targeted cancer therapeutics. For more information, please visit https://www.trovagene.com.

Forward-Looking Statements

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of words such as "anticipate," "believe," "forecast," "estimated" and "intend" or other similar terms or expressions that concern Trovagene's expectations, strategy, plans or intentions. These forward-looking statements are based on Trovagene's current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, our need for additional financing; our ability to continue as a going concern; clinical trials involve a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results; our clinical trials may be suspended or discontinued due to unexpected side effects or other safety risks that could preclude approval of our product candidates; uncertainties of government or third party payer reimbursement; dependence on key personnel; limited experience in marketing and sales; substantial competition; uncertainties of patent protection

and litigation; dependence upon third parties; our ability to develop tests, kits and systems and the success of those products; regulatory, financial and business risks related to our international expansion and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. There are no guarantees that any of our technology or products will be utilized or prove to be commercially successful, or that Trovagene's strategy to design its liquid biopsy tests to report on clinically actionable cancer genes will ultimately be successful or result in better reimbursement outcomes. Additionally, there are no guarantees that future clinical trials will be completed or successful or that any precision medicine therapeutics will receive regulatory approval for any indication or prove to be commercially successful. Investors should read the risk factors set forth in Trovagene's Form 10-K for the year ended December 31, 2017, and other periodic reports filed with the Securities and Exchange Commission. While the list of factors presented here is considered representative, no such list should be considered to be a complete statement of all potential risks and uncertainties. Unlisted factors may present significant additional obstacles to the realization of forward-looking statements. Forward-looking statements included herein are made as of the date hereof, and Trovagene does not undertake any obligation to update publicly such statements to reflect subsequent events or circumstances.

Trovagene Contact:
Vicki Kelemen
VP, Corporate Communications
858-952-7652
[e-mail]



Cision View original content with multimedia:http://www.prnewswire.com/news-releases/trovagene-receives-positive-opinion-for-orphan-drug-designation-in-the-european-union-for-pcm-075-trovagenes-investigational-cancer-drug-300689776.html

SOURCE Trovagene, Inc.


Copyright 2018 PR Newswire

[$Pistol Pete$]

$MNKD Daily and Weekly Charts

[$Pistol Pete$]

$TROV Trovagene Receives Positive Opinion for Orphan Drug Designation in the European Union for PCM-075, Trovagene's Investigational Cancer Drug TROV

https://www.nasdaq.com/press-release/trovagene-receives-positive-opinion-for-orphan-drug-designation-in-the-european-union-for-pcm075-20180801-00539

[$Pistol Pete$]

$MNKD MannKind and Tanner Pharma Group Enter into an ex-U.S. Distribution Agreement for Afrezza® MNKD

https://www.nasdaq.com/press-release/mannkind-and-tanner-pharma-group-enter-into-an-exus-distribution-agreement-for-afrezza-20180727-00553

[$Pistol Pete$]

$PMCB PharmaCyte Biotech Successfully Completes Another Study on the Encapsulated Cells Used in Its Pancreatic Cancer Therapy PMCB



Press Release | 07/23/2018
PharmaCyte Biotech, Inc. (OTCQB: PMCB), a clinical stage biotechnology company focused on developing targeted cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced that it has successfully completed a study on the stability after “hand thawing” syringes of the Cell-in-a-Box® encapsulated cells that will be used, in combination with low doses of the cancer prodrug ifosfamide, for the treatment of locally advanced, non-metastatic, inoperable pancreatic cancer (LAPC). The data obtained from this “hand thawing” study is required by the U.S. Food and Drug Administration (FDA).

The filing of an Investigational New Drug Application (IND) requires that the clinical product, as well as the product’s use, should be well characterised. PharmaCyte’s Cell-in-a-Box® is a cutting edge Advanced Therapy Medicinal Product (ATMP). Therefore, numerous studies are needed since such a product has never been tested before in the United States. The laboratory scale “thawing” study previously conducted (http://pharmacyte.com/pharmacyte-announces-successful-completion-6-month-stability-study-encapsulated-cells-clinical-trial/) determined how long the once-frozen Cell-in-a-Box® encapsulated cells are still fit for use after thawing, as would occur in a clinical setting before the Cell-in-a-Box® capsules are implanted into a patient with LAPC. That study defined one of the important parameters for the upcoming planned clinical trial for LAPC.

At individual study sites, the frozen cells in the Cell-in-a-Box® capsules within syringes will be hand-thawed and then kept at room temperature until they are implanted into a patient with LAPC. The results of the “hand thawing” study announced today show that the viability of the cells remains essentially the same for at least 30 minutes at room temperature. This serves to define the time that the interventional radiologist has to implant the Cell-in-a-Box® capsules after thawing to ensure cellular viability within the patient.

PharmaCyte’s Chief Executive Officer, Kenneth L. Waggoner, explained the significance of the study saying, “This is yet another important study that PharmaCyte has completed to comply with the FDA’s requirements for our planned, upcoming clinical trial in LAPC. The Cell-in-a-Box® encapsulated cells are in a frozen state before they are administered to the patient. This study was designed to determine how long after unfreezing the Cell-in-a-Box® encapsulated cells can they be held at room temperature before being introduced into the patient without losing their effectiveness.

“This is important since the treatment depends on the viability of our genetically engineered live human cells in order to produce the cytochrome P450 enzyme for the activation of the chemotherapy prodrug ifosfamide. The study’s goal was to determine how long the cells remained viable at room temperature after thawing; thus, mimicking how long the clinicians and interventional radiologists will have to administer the capsules to the patient in the hospital. The newly completed studies show how long that Cell-in-a-Box® encapsulated cells can be kept at room temperature for optimal activity.”

About PharmaCyte Biotech

PharmaCyte Biotech is a clinical stage biotechnology company developing cellular therapies for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as “Cell-in-a-Box®.” This technology will be used as a platform upon which therapies for several types of cancer and diabetes are being developed.

PharmaCyte’s therapy for cancer involves encapsulating genetically engineered human cells that convert an inactive chemotherapy drug into its active or “cancer-killing” form. For pancreatic cancer, these encapsulated cells are implanted in the blood supply to the patient’s tumor as close as possible to the site of the tumor. Once implanted, a chemotherapy drug that is normally activated in the liver (ifosfamide) is given intravenously at one-third the normal dose. The ifosfamide is carried by the circulatory system to where the encapsulated cells have been implanted. When the ifosfamide flows through pores in the capsules, the live cells inside act as a “bio-artificial liver” and activate the chemotherapy drug at the site of the cancer. This “targeted chemotherapy” has proven effective and safe to use in past clinical trials and results in no treatment related side effects.

PharmaCyte’s therapy for Type 1 diabetes and insulin-dependent Type 2 diabetes involves encapsulating a human cell line that has been genetically engineered to produce, store and release insulin in response to the levels of blood sugar in the human body and/or beta islet cells. The encapsulation will be done using the Cell-in-a-Box® technology. Once the encapsulated cells are implanted in a diabetic patient, they will function as a “bio-artificial pancreas” for purposes of insulin production.

Safe Harbor

This press release contains forward-looking statements, which are generally statements that are not historical facts. Forward-looking statements can be identified by the words "expects," "anticipates," "believes," "intends," "estimates," "plans," "will," "outlook" and similar expressions. Forward-looking statements are based on management's current plans, estimates, assumptions and projections, and speak only as of the date they are made. We undertake no obligation to update any forward-looking statement because of new information or future events, except as otherwise required by law. Forward-looking statements involve inherent risks and uncertainties, most of which are difficult to predict and are generally beyond our control. Actual results or outcomes may differ materially from those implied by the forward-looking statements due to the impact of numerous risk factors, many of which are discussed in more detail in our Annual Report on Form 10-K and our other reports filed with the Securities and Exchange Commission.

More information about PharmaCyte Biotech can be found at www.PharmaCyte.com. Information may also be obtained by contacting PharmaCyte’s Investor Relations Department.


View source version on businesswire.com: https://www.businesswire.com/news/home/20180723005348/en/

[$Pistol Pete$]

$LVGI Volume speak for itself. Summer is over and traders love potential play. I think LVGI is the right choice

[$Pistol Pete$]

Her 2nd treatment was amazing. No side effect at all. Heading home today

[$Pistol Pete$]

GM Mick. My Mom third chemo treatment went well and no side effect again. Thanks God

[$Pistol Pete$]

$ZMRK https://andovercaller.com/gearing-for-a-bull-run-zalemark-holding-co-zmrk-moves-33-33-for-week/294812/ Gearing for a bull run? Zalemark Holding Co (ZMRK) Moves 33.33% For Week
Andover Caller - 18h ago


Zalemark Holding Co (ZMRK) shares are showing positive momentum over the past week as the stock has clocked in with gains of 33.33%. Gearing for a bull run? Zalemark Holding Co (ZMRK) Moves 33.33% For Week
Andover Caller - 18h ago


Zalemark Holding Co (ZMRK) shares are showing positive momentum over the past week as the stock has clocked in with gains of 33.33%.

[$Pistol Pete$]

$IBM MARKET SNAPSHOT: Stocks Set To Attempt Rebound After Last Week's Slide

Source: Dow Jones News
By William Watts, MarketWatch

IBM to acquire Red Hat in $33 billion deal

U.S. stock-index futures pointed to a higher start for Wall Street, as investors readied to attempt a bounce back from the previous week's steep losses, ahead of another heavy week of earnings data.

What are major benchmarks doing?

S&P 500 futures rose 0.8% to 2,692, while futures on the Dow Jones Industrial Average rose 104 points, or 0.4%, to 24,852. Nasdaq-100 futures rose 1.2% to 6,975.

Last week saw the S&P 500 drop 3.9% to end Friday at 2,658.69, leaving it 8.8% lower in the month to date, while the Dow dropped 3% last week to 24,688.31, leaving it 6.7% lower for the month. Last week's carnage saw both the S&P and Dow turn negative for the year.

The tech-heavy Nasdaq Composite led the way lower for major indexes last week, dropping 3.8% and falling into correction territory, defined as a pullback of 10% or more from a recent peak.

What's driving the market?

Analysts are attributing the stock market's October weakness to a variety of factors, including concerns about global and domestic growth prospects, worries that U.S. corporate earnings growth has peaked, and fears of a U.S. monetary policy misstep by the Federal Reserve.

Earnings season has seen companies continue to beat earnings and sales expectations, but analysts said weak guidance from some companies may have undercut performance. Through Friday, 240 S&P 500 companies had reported quarterly results, with 81% topping expectations, according to Jefferies.

What are analysts saying?

The selloff "appears to have overshot the fundamentals. We expect continued positive economic data and prospective EPS (earnings per share growth) to support an S&P 500 rebound to our year-end target of 2,850," wrote analysts led by David Kostin at Goldman Sachs, in a note.

What stocks are in focus?

Shares of Red Hat Inc. (RHT) jumped 52% in premarket trade to $176.99 after International Business Machines Corp. (IBM) said it would acquire the open-source software company (http://www.marketwatch.com/story/ibm-to-buy-red-hat-for-63-premium-in-big-play-for-the-cloud-2018-10-28)for $190 a share in cash deal. Shares of IBM were off 5% in premarket action.

Northrop Grumman (NOC) on Monday announced a $1 billion accelerated stock repurchase agreement (http://www.marketwatch.com/story/northrop-grumman-sets-1-billion-accelerated-stock-repurchase-program-2018-10-29) with Goldman Sachs & Co. (GS).


(END) Dow Jones Newswires

October 29, 2018 07:23 ET (11:23 GMT)

Copyright (c) 2018 Dow Jones & Company, Inc.

[$Pistol Pete$]

$ZMRK ~ Welcome to Zalemark Holding Co.; Inc. (ZMRK) DD

Company Profile

About the Company

www.zalemark.com/?page_id=5

Zalemark Holding Company was formed in 2003 and became public in 2007 operating under the trading symbol ZMRK. Zalemark is a Delaware Corporation with accounting operations in Los Angeles, & Mfg. facilities in Bangkok, Thailand. ZMRK uses the latest state of the art CAD designing equipment and Mfg. production lines capable of volumes from 10 to 100,000 units with precise quality control. Zalemark’s slogan is, “The Mark of Quality” as we pride ourselves on providing the best quality at any price point while maintaining our reputation in the industry by using socially conscience materials and labor. Steven Zale our visionary designer has received many accolades in his design career not limited to De Beers, Forbes and Cosmopolitan. Steven’s ability to capture a brand and articulate it through design while remaining on the leading edge of fashion and style has made him the behind the scenes “go to” guy for many popular brands today.









About Company History



Investor Relations

Zalemark Holding Company is a product branding company. We design, develop, manufacture and market branded products through our extensively-developed distribution channels with a special emphasis on well known brands and celebrity-endorsed products. While our current focus is the launch of major brands into the jewelry industry, we continue to incorporate our expertise in luxury into our designs. We are exploring other opportunities where we can develop lasting designs and trends.

Zalemark sources socially responsible materials, harnesses the creative ingenuity of Steven Zale, one of the jewelry industry’s most dynamic, progressive designers, captures the essence and spirit of a brand and then brings it innovatively and decisively to the marketplace through established distribution channels.

We seek a rapport with our clients and our customers, and they appreciate the quality and integrity we bring to every facet of business. It is important to us to reach out to others and we do so through our commitment and support to Operation Smile, which helps transform the lives of children all over the world one smile at a time.

www.zalemark.com/?page_id=9


$ZMRK recent news/filings

## source: finance.yahoo.com

Wed, 08 Jul 2015 13:00:00 GMT ~ Zalemark Projects Second Quarter Revenue to Exceed over 649.8%

[Accesswire] - Zalemark Holding Company, Inc. Projects that 2nd Quarter Revenue to Increase Over 1865% Over Last Year LOS ANGELES, CA / ACCESSWIRE / July 8, 2015 / Zalemark Holding Company, Inc. (OTC: ZMRK) is currently ...

read full: http://finance.yahoo.com/news/zalemark-projects-second-quarter-revenue-130000256.html
*********************************************************

Fri, 01 May 2015 13:00:00 GMT ~ Photo Release -- Zalemark to Debut the Crayola Fine Jewelry Collection in Las Vegas

[GlobeNewswire] - LOS ANGELES -- Crayola is an iconic part of childhood and it's only natural that only Crayola colors would continue to be part of adulthood. Zalemark (OTC:ZMRK) and award winning designer Steven Zale have ...

read full: http://finance.yahoo.com/news/photo-release-zalemark-debut-crayola-130000449.html
*********************************************************

Tue, 24 Feb 2015 14:47:00 GMT ~ Zalemark Holding Company to Unveil New Brand "Infinite Love" By The Morgans (BTM) at The 2015 Childrens United Nations Oscar's Event

[Accesswire] - LOS ANGELES, CA / ACCESSWIRE / February 24, 2015 / Zalemark Holding Company, Inc. (PINKSHEETS:ZMRK), the renowned jewelry design, product development, and branding company will co-participate in the 2015 ...

read full: http://finance.yahoo.com/news/zalemark-holding-company-unveil-brand-144700511.html
*********************************************************

Wed, 18 Feb 2015 14:00:00 GMT ~ Valentine's Day Launch Sell Out for Engelbert Humperdinck, The King of Romance, New Exquisite Jewelry Line with Zalemark

[Accesswire] - LOS ANGELES, CA / ACCESSWIRE / February 18, 2015 / Legendary music artist Engelbert Humperdinck proudly announces his first ever jewelry collaboration with Zalemark Holding Company (OTC: ZMRK). The King ...

read full: http://finance.yahoo.com/news/valentines-day-launch-sell-engelbert-140000101.html
*********************************************************

$ZMRK charts

basic chart ## source: stockcharts.com



basic chart ## source: stockscores.com



big daily chart ## source: stockcharts.com



big weekly chart ## source: stockcharts.com


$ZMRK company information

## source: otcmarkets.com

Link: http://www.otcmarkets.com/stock/ZMRK/company-info
Ticker: $ZMRK
OTC Market Place: OTC Pink Current
CIK code: not found
Company name: Zalemark Holding Co., Inc.
Company website: http://www.zalemark.com
Incorporated In: DE, USA

Business Description: Zalemark Holding Company, Inc. is a publicly traded OTC company under the symbol \"ZMRK\". Zalemark is an award winning product design, development, manufacturing and distribution company. Zalemark also operates, stevenzale.com, LuxTV, Inc. dba Luxury Brands Group, Demeter Brand, Divas Choice Brand, Dog Boxer Brand, and Compralux Hispanic Shopping Network. These brands are widely known for their, \"Mark of Quality\" the companies' standard associated in all aspects of their business.



$ZMRK share structure

## source: otcmarkets.com

Market Value: $2,006,676 a/o Jul 16, 2015
Shares Outstanding: 62,708,631 a/o Dec 31, 2014
Float: 26,592,181 a/o Dec 31, 2014
Authorized Shares: 75,000,000 a/o Dec 31, 2014
Par Value: 0.0001
$ZMRK extra dd links

Company name: Zalemark Holding Co., Inc.
Company website: http://www.zalemark.com

## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/ZMRK/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/ZMRK/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=ZMRK+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=ZMRK+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=ZMRK+Industry

## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/ZMRK/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/ZMRK/news - http://finance.yahoo.com/q/h?s=ZMRK+Headlines

## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/ZMRK/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/ZMRK/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/ZMRK/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/ZMRK/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/ZMRK/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/ZMRK/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/ZMRK/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/ZMRK/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=ZMRK+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/ZMRK
DTCC (dtcc.com): http://search2.dtcc.com/?q=Zalemark+Holding+Co.%2C+Inc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=Zalemark+Holding+Co.%2C+Inc.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=Zalemark+Holding+Co.%2C+Inc.&x=0&y=0
WHOIS (domaintools.com): http://whois.domaintools.com/http://www.zalemark.com
Alexa (alexa.com): http://www.alexa.com/siteinfo/http://www.zalemark.com#
Corporate website internet archive (archive.org): http://web.archive.org/web/*/http://www.zalemark.com

## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/ZMRK/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/ZMRK
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/ZMRK/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/ZMRK/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/ZMRK/sec-filings
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/ZMRK/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/ZMRK/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/ZMRK/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/ZMRK/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=ZMRK&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=ZMRK
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/ZMRK/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=ZMRK+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=ZMRK+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=ZMRK
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=ZMRK
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=ZMRK+Cash+Flow&annual

## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/ZMRK/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=ZMRK+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/ZMRK.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=ZMRK
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/ZMRK/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/ZMRK/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/ZMRK/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/ZMRK/insider-transactions

## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/ZMRK
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/ZMRK
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/ZMRK:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=ZMRK
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=ZMRK

[$Pistol Pete$]

$AAPL Daily and Weekly Charts

[insymbols]

Charles & Colvard, Ltd. $CTHR versus Bergio International $BRGO Financial Analysis https://t.co/KhEPsbvGBa

[insymbols]

$IQ iQIYI Inc.

[insymbols]

$IQ iQIYI Inc.

[$Pistol Pete$]

$ZMRK check out this link and see ZMRK in motion

http://investorshub.advfn.com/boards/msgsearch.aspx?searchstr=ZMRK



Go $ZMRK

[$Pistol Pete$]

$BPTH Bio-Path Announces Clinical Update to Interim Analysis of Phase 2 Prexigebersen Trial in Acute Myeloid Leukemia
Interim Data Update from Phase 2 Study Demonstrates Meaningful Clinical Improvement with Excellent Patient Safety Profile

Company Provides Clinical Development Plan with Pathways to Registration

HOUSTON, March 06, 2019 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announces a clinical update to the previously reported interim analysis from the Phase 2 trial of prexigebersen (BP1001) for the treatment of acute myeloid leukemia (AML) and provides its plans for the compound’s clinical development moving forward toward registration.

The open-label Phase 2 study in Stage 1 evaluated the efficacy and safety of prexigebersen in conjunction with low dose cytarabine (LDAC), a therapeutic regimen well-established in treatment of AML patients who cannot or elect not to be treated with more intensive chemotherapy. The primary objective of the study is to determine whether the combination of prexigebersen and LDAC provides greater efficacy than would be expected with LDAC alone in a de novo patient population. Subsequently, Stage 2 of the study added a second cohort that is evaluating the efficacy and safety of prexigebersen in conjunction with Decitabine in addition to the cohort evaluating prexigebersen in conjunction with LDAC.

In April 2018, Bio-Path completed an initial interim analysis of 17 evaluable patients from Stage 1 of the Phase 2 study. These results showed a promising safety and efficacy profile with 47% of patients having a response comprised of four complete response (CR) patients, including one CRi (complete response with incomplete hematologic recovery) and four patients with stable disease. Recently, the data from the 17 evaluable patients was updated, and following a meeting with the principal investigators of the study, those results now show that the efficacy profile has improved to where 11 (65%) of the 17 evaluable patients had a response, including five (29%) who achieved CR (including one CRi) and one morphologic leukemia free state (MLFS), and six stable disease responses, including two patients who had greater than a 50% reduction in bone marrow blasts. Importantly, through investigation by the principal investigators, it was observed that 68% of these patients were secondary AML patients, an extremely difficult class to treat.

The efficacy data from the 17 evaluable patients was very favorable in this challenging population compared to the reported CR (complete response), CRp (complete response with incomplete platelet recovery), and CRi rates with LDAC treatment alone of 7-13%1 in this patient population. Additionally, a study of newly approved Venetoclax plus LDAC in these newly diagnosed patients reported a 42% CR/CRh (complete response with incomplete hematologic response) response rate; however, this study had only 46% secondary AML compared to 68% in the Bio-Path 17-patient interim analysis.

“These updated interim data from Stage 1 of our Phase 2 study of prexigebersen in de novo AML patients give strong evidence of the safety and efficacy profile of our lead compound and underscore its potential to provide meaningful treatment improvement in this difficult-to-treat patient population,” said Peter Nielsen, President and Chief Executive Officer of Bio-Path. “We were particularly pleased with these results, especially when you consider that the large percentage of these patients are secondary AML patients. The CR/CRp/CRi rate for LDAC treatment alone for the class of patients in this study was benchmarked at 7-13%1, whereas prexigebersen treatment with LDAC is currently showing a 29% CR/CRi/MLFS rate, with a highly favorable safety profile.”

“Prexigebersen with its efficacy and safety profile, is an ideal combination candidate with frontline therapy. Our aim is to match prexigebersen with the leading frontline therapies to improve treatment options for patients. Consequently, we maintain an in-depth knowledge of all new therapies and therapies in development. As the treatment landscape evolves, we continue to nimbly respond to those advances and the plans for our registration-directed clinical development program for prexigebersen as a treatment for AML reflects these changes,” concluded Mr. Nielsen.

The recent approval of the frontline therapy Venetoclax provides an opportunity for combining prexigebersen with the combination Venetoclax plus Decitabine for the treatment of de novo AML patients. Venetoclax is a drug whose activity is against the anti-apoptotic protein Bcl-2 based on neutralizing the protein’s BH3 domain. It is also an approved treatment in chronic lymphocytic leukemia (CLL) patients; however, with the exception of some patients treated with allogeneic hematopoietic cell transplantation (HCT), disease relapse invariably occurs, often times due to BH3 domain mutation over time. Bio-Path’s BP1002 is a drug candidate that targets the Bcl-2 protein, just as Venetoclax. However, BP1002 activity is based on blocking the Bcl-2 messenger RNA, and not the BH3 domain. As a result, Bio-Path believes that BP1002 could provide an alternative to Venetoclax CLL patients who have relapsed. Likewise, Bio-Path believes there will be AML patient relapses from Venetoclax treatments, representing an additional opportunity for Bio-Path to treat those patients with BP1002.

As a result, Bio-Path intends to file for registration of BP1002 for the treatment of Venetoclax relapses in both CLL patients and AML patients. The planned modification of the Company’s Phase 2 clinical program in AML to include Venetoclax combination treatment with prexigebersen will give Bio-Path early experience with treating Bcl-2 driven anti-apoptosis in these patients.

Registrational Clinical Development Program

After treating nearly 70 patients, Bio-Path believes it now has a plan with definable paths to registration. Results to date have shown prexigebersen, with its efficacy and safety profile, to be an ideal combination candidate with frontline therapy. The Principal Investigators of the Phase 2 study and Bio-Path’s Scientific Advisory Board helped prepare the revised clinical program for prexigebersen in AML. The new registration-directed plan is as follows:

Amend the existing Stage 2 prexigebersen + Decitabine Phase 2 AML cohort in untreated de novo patients to add untreated high risk myelodysplastic syndrome (MDS) patients. High risk MDS patients are typically treated with Hypomethylating agents alone and the combination treatment may benefit these patients.
Cancel the Stage 2 prexigebersen + LDAC Phase 2 AML cohort in untreated de novo patients. Although Bio-Path has had good success with prexigebersen + LDAC, there is a strong preference by oncologists for Decitabine over LDAC as the combination therapy drug partner in treating these patients.
Amend the existing Phase 2 protocol to add a cohort of prexigebersen in combination with Decitabine in refractory/relapsed AML patients. This is based on the Company’s experience in this setting, including the Phase 1b safety segment combination treatment in refractory/relapsed patients. Refractory/relapsed high risk MDS patients will be included in this cohort.
Preclinical efficacy studies are underway for prexigebersen + Decitabine + Venetoclax triple combination to confirm the incremental efficacy benefit of the triple combination.
Amend the protocol of the Phase 2 trial to perform a small safety assessment of the triple combination prexigebersen + Decitabine + Venetoclax in the refractory/relapsed AML plus high risk MDS patient cohort.
Following a successful safety assessment, initiate a registration-directed cohort of the trial by adding Venetoclax to the prexigebersen + Decitabine combination treatment of refractory/relapsed AML plus high risk MDS patients.
Amend the protocol of the Phase 2 trial to initiate a Prexigebersen + Decitabine + Venetoclax registration-directed trial for untreated AML and high risk MDS patients, to determine if more durable responses and longer survival is observed compared to patients treated with the Decitabine + Venetoclax combination.
The result from these transformational steps will be two registration-directed cohorts of Bio-Path’s Phase 2 clinical trial in AML, both studying the triple combination prexigebersen + Decitabine + Venetoclax but in two separate patient populations, including untreated AML plus untreated high risk MDS patients, and refractory/relapsed AML plus refractory/relapsed high risk MDS patients. Bio-Path expects that many of the Venetoclax patients will relapse and that Bio-Path second drug candidate BP1002 targeted to Bcl-2 can replace Venetoclax enabling continued patient treatment with the triple combination. We expect this to result in a third registration-directed clinical program, specifically for BP1002 in Venetoclax treatment failures.

1 Heiblig, Mediterr J Hematol 2016; Kantarjian, J Clin Oncol 2012; Dohner, Blood 2014.

About Bio-Path Holdings, Inc.

Bio-Path is a biotechnology company developing DNAbilize®, a novel technology that has yielded a pipeline of RNAi nanoparticle drugs that can be administered with a simple intravenous transfusion. Bio-Path’s lead product candidate, prexigebersen (BP1001, targeting the Grb2 protein), is in a Phase 2 study for blood cancers and in preclinical studies for solid tumors. This is followed by BP1002, targeting the Bcl-2 protein, which the company anticipates entering into clinical studies where it will be evaluated in lymphoma and solid tumors.

For more information, please visit the Company's website at http://www.biopathholdings.com.

Forward-Looking Statements

This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws. These statements are based on management's current expectations and accordingly are subject to uncertainty and changes in circumstances. Any express or implied statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Any statements that are not historical facts contained in this release are forward-looking statements that involve risks and uncertainties, including Bio-Path’s ability to raise needed additional capital on a timely basis in order for it to continue its operations, Bio-Path's ability to have success in the clinical development of its technologies, the timing of enrollment and release of data in such clinical studies and the accuracy of such data, limited patient populations of early stage clinical studies and the possibility that results from later stage clinical trials with much larger patient populations may not be consistent with earlier stage clinical trials, the maintenance of intellectual property rights, risks relating to maintaining Bio-Path's listing on the Nasdaq Capital Market and such other risks which are identified in Bio-Path's most recent Annual Report on Form 10- K, in any subsequent quarterly reports on Form 10-Q and in other reports that Bio-Path files with the Securities and Exchange Commission from time to time. These documents are available on request from Bio-Path Holdings or at www.sec.gov. Bio-Path disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Contact Information:

Investors

Will O’Connor
Stern Investor Relations
212-362-1200
[e-mail]

Doug Morris
Investor Relations
Bio-Path Holdings, Inc.
832-742-1369

Source: Bio-Path Holdings, Inc.
© 2019 GlobeNewswire, Inc.

[$Pistol Pete$]

$NIO buying the dip

[beambe]

Robotics CVRS

[$Pistol Pete$]

$ZMRK Barchart Opinion 100% "BUY"....reverse merger is coming
https://www.barchart.com/stocks/quotes/ZMRK/opinion

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147053756

[$Pistol Pete$]

$NIO Goldman Sachs Group Initiates Coverage on NIO (NIO). The firm set a “buy” rating and a $10.70 price target on the stock.

https://theenterpriseleader.com/2019/03/09/goldman-sachs-group-initiates-coverage-on-nio-nio.html

[$Pistol Pete$]

$NIO Bjørn Nyland Checks Out The NIO ES8 Electric SUV: Video NIO

https://insideevs.com/bjorn-nyland-checked-the-nio-es8-video/

[$Pistol Pete$]

$PMCB PharmaCyte Biotech Nearing Major Milestone—An Open IND with the FDA PMCB


https://www.nasdaq.com/press-release/pharmacyte-biotech-nearing-major-milestonean-open-ind-with-the-fda-20190204-00608

[abazaba375]

$ETEK looking good https://ih.advfn.com/p.php?pid=chartscreenshot&u=l9waWQ%2B63K%2Flc1OCXihFhhxA%2FdbEfwnuydBM%2FFkIHus%3D&kslash=s

[$Pistol Pete$]

$NIO Goldman Sachs Group Initiates Coverage on NIO (NIO). The firm set a “buy” rating and a $10.70 price target on the stock.

https://theenterpriseleader.com/2019/03/09/goldman-sachs-group-initiates-coverage-on-nio-nio.html

[$Pistol Pete$]

$NIO NIO Patent Application Just Puts The Speakers Anywhere In Your EV

https://www.forbes.com/sites/sebastianblanco/2019/03/29/nio-patent-application-just-puts-the-speakers-anywhere-in-your-ev/

[$Pistol Pete$]

$MNKD $MNKD MannKind Receives $12.5 Million Milestone Payment from United Therapeutics

Source: GlobeNewswire Inc.

MannKind Corporation (NASDAQ: MNKD) today announced that it achieved the first of several specified development milestones under its licensing and collaboration agreement with United Therapeutics for the development and commercialization of a dry powder formulation of treprostinil. Treprostinil Technosphere (“TreT”) is an investigational product currently being evaluated in clinical trials for the treatment of pulmonary arterial hypertension. Pursuant to the agreement, MannKind is eligible to earn additional payments up to $37.5 million upon the achievement of other defined development milestones. MannKind will also be entitled to receive low double-digit royalties on net sales of TreT.
MannKind also announced that it filed a new shelf registration statement on Form S-3 with the Securities and Exchange Commission on March 29, 2019, which, when effective, will replace the existing shelf registration statement that expires on April 27, 2019.

About MannKind Corporation

MannKind Corporation (Nasdaq: MNKD) focuses on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. MannKind is currently commercializing Afrezza® (insulin human) Inhalation Powder, the Company's first FDA-approved product and the only inhaled rapid-acting mealtime insulin in the United States, where it is available by prescription from pharmacies nationwide. MannKind is headquartered in Westlake Village, California, and has a state-of-the art manufacturing facility in Danbury, Connecticut. The Company also employs field sales and medical representatives across the U.S.

For further information, visit www.mannkindcorp.com.

Company Contact:
Rose Alinaya
SVP, Investor Relations
818.661.5000
[e-mail]


MannkindLogoStackedPreferd.jpg

[$Pistol Pete$]

$NIO Nio Put Buyers Pounce as Citi Screams "Buy" NIO

https://finance.yahoo.com/news/nio-put-buyers-pounce-citi-171749824.html

[$Pistol Pete$]

$NIO this will continue to consolidate this week, as shorts continue to cover on every dip. Expect moves up next week come the Auto show.

[$Pistol Pete$]

$NIO China’s NIO expands mobile charging service to all electric cars, including Tesla

https://www.teslarati.com/tesla-nio-mobile-charging-services-china/

[$Pistol Pete$]

$NIO In photos: Dive into the world of Chinese cars and SUVs at Auto Shanghai 2019 NIO

https://newatlas.com/auto-shanghai-2019-gallery/59374/

[mick]

Cambria Trinity ETF (CBOE:TRTY) is an actively managed fund that also uses the ETF of ETFs methodology. While TRTY is an active fund, it aims to replicate or beat the performance of the Cambria Trinity Index, a benchmark that “employs a balanced, systematic approach to asset allocation, focusing on diversification, value investing, and trend following,” according to Cambria.

Several factors make TRTY one of the best ETFs for conservative investors. For starters, its roster of 18 funds makes this one of the largest ETFs of ETFs in terms of depth. Second, TRTY offers diversification across asset classes, including domestic and foreign bonds and stocks as well as managed futures strategies. By virtue of its robust fixed-income exposure and positions in two Cambria shareholder yield ETFs, TRTY is a great ETF.

The Cambria Global Momentum ETF (CBOE:GMOM) accounts for roughly a third of TRTY’s weight. GMOM is rooted in momentum and trend following.

[$Pistol Pete$]

$AAPL Apple Previews iOS 13

Source: Business Wire
Introduces Dark Mode, Advanced Photo and Camera Features, Sign In with Apple and an All-New Maps Experience

Apple® today previewed iOS 13, introducing a dramatic new look for iPhone® with Dark Mode and new ways to browse and edit photos, sign in to apps and websites, and navigate the world with an all-new map. iOS 13 is faster and more responsive with optimizations across the system that improve app launch, reduce app download sizes and make Face ID® even faster.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190603005711/en/

iOS 13 brings exciting new features to popular apps this fall. (Photo: Business Wire)
iOS 13 brings exciting new features to popular apps this fall. (Photo: Business Wire)

“iOS 13 brings new capabilities to the apps you use every day, with rich updates to Photos and Maps, and privacy-protecting features like Sign In with Apple, all while delivering faster performance,” said Craig Federighi, Apple’s senior vice president of Software Engineering. “We’re excited for customers to experience what’s coming to iPhone this fall and can’t wait for them to see how great everything looks in Dark Mode.”

Dark Mode: A Dramatic New Look for iPhone

iPhone has a beautiful new look with Dark Mode, a new dark color scheme that works system-wide and across all native apps to deliver a great viewing experience, especially in low-light environments. Dark Mode is available to third-party app developers for integration into their own apps and can be scheduled to turn on automatically at sunset or at a certain time.

Easier Browsing and Powerful Editing Tools for Photos

Using on-device machine learning, Photos curates the entire library to highlight the best images, automatically hiding clutter and similar photos to showcase significant events from the past day, month or year. Photos and videos are intelligently organized, making it easier to browse, discover and relive favorite memories, with auto play videos to bring the library to life.

Photo editing is more comprehensive and intuitive with new tools that are easier to apply, adjust and review at a glance. With just a swipe, effects can be increased or decreased to create the perfect look, providing photographers with more creative possibilities and control over their images. And in iOS 13, most photo editing tools are now available for video editing, making it possible to rotate, crop or apply filters right within the Photos app.

With iOS 13, Portrait Lighting adjustments can be made right in the Camera app to virtually move the light closer to sharpen eyes and brighten and smooth facial features, or push the light farther away to create a subtle, refined look. A new High-Key Mono effect creates a beautiful, monochromatic look for Portrait mode photos.

Fast, Easy and Private Sign In with Apple

Apple is introducing a new, more private way to simply and quickly sign into apps and websites. Instead of using a social account or filling out forms, verifying email addresses or choosing passwords, customers can simply use their Apple ID to authenticate and Apple will protect users' privacy by providing developers with a unique random ID. Even in cases where developers choose to ask for a name and email address, users have the option to keep their email address private and share a unique random email address instead. Sign In with Apple makes it easy for users to authenticate with Face ID or Touch ID® and has two-factor authentication built in for an added layer of security. Apple does not use Sign In with Apple to profile users or their activity in apps.

All-New Maps Experience

Apple Maps helps millions of people navigate and explore the world, all while protecting user privacy. After driving 4 million miles to rebuild the basemap from the ground up, Apple is delivering a new Maps experience with broader road coverage, better pedestrian data, more precise addresses and more detailed landcover. The new map is available now in select cities and states, and will roll out across the US by the end of 2019 and to more countries in 2020.

Powered by the new basemap and high-resolution 3D photography, a new Look Around feature delivers beautiful street-level imagery of a city with smooth and seamless transitions. iOS 13 brings additional new features to the Maps app, including Collections to easily share favorite restaurants, travel destinations or places to shop with friends, and Favorites for navigating to frequent destinations, such as home, work, the gym or school, with a simple tap from the launch screen.

Additional iOS 13 Features

Reminders has a new look and offers intelligent ways to create and edit reminders, with more ways to organize and keep track of them. The quick toolbar makes it easier to add times, dates, locations and flags, or add attachments. With deeper integration with Messages, it’s easy to tag someone in a reminder so that it surfaces when the user messages with that person.
Messages can automatically share a user’s name and photo, or customized Memoji™ or Animoji®, to easily identify who is in the Messages thread. Memoji are automatically made into sticker packs built into the iOS keyboard, so they can be used in Messages, Mail and other apps. Memoji also feature new hairstyles, headwear, makeup, piercings and accessories.
Siri® has a new, more natural voice, and Siri Shortcuts now supports Suggested Automations that provide personalized routines for things like heading to work or going to the gym.
CarPlay® gets its biggest update ever with a new Dashboard to view music, maps and more in a single view, a new Calendar app and Siri support for third-party navigation and audio apps.
HomePod™ can distinguish voices from anyone in the home to deliver personal requests, including messages, music and more. Live radio gives Siri access to over 100,000 radio stations from iHeartRadio, Radio.com and TuneIn, and a new sleep timer turns off music after a set amount of time. Handoff® enables users to easily move music, podcasts or a phone call to HomePod when they arrive home.
With AirPods®, Siri can read incoming messages as soon as they arrive, from Messages or any SiriKit™-enabled messaging app. A new audio sharing feature makes it easy to watch a movie or share a song with a friend by simply bringing a second pair close to iPhone or iPad®.
Voice Control provides a powerful new experience that enables users to operate their iPhone, iPad or Mac® entirely by their voice. Using the latest Siri speech recognition technology, Voice Control gets even more accurate text transcription and editing.1
Notes has a new Gallery View, more powerful collaboration with shared folders, new search tools and checklist options.
QuickPath brings easy one-hand typing to the iOS keyboard by continuously swiping through the letters of a word.2
Text Editing is enhanced, making scrolling documents, moving the cursor and selecting text faster and more accurate.
Files app introduces the ability to share folders with iCloud Drive® and access files from external storage devices like SD cards and USB flash drives.
Health offers ways to monitor hearing health and brings new ways to track, visualize and predict a woman’s menstrual cycle.
Location Services controls give users more choices for how they share location data with apps, including a new one-time location option and more information on when apps are using location in the background.
Performance improvements make the entire system more responsive with faster Face ID unlock, and a new way to package iPhone apps on the App Store® that reduces app download sizes by up to 50 percent, makes app updates over 60 percent smaller and results in apps launching up to twice as fast.
Availability

The developer preview of iOS 13 is available to Apple Developer Program members at developer.apple.com starting today, and a public beta program will be available to iOS users later this month at beta.apple.com. New software features will be available this fall as a free software update for iPhone 6s and later, and will be available with iPadOS™ for iPad Air® 2 and later, all iPad Pro® models, iPad 5th generation and later, and iPad mini® 4 and later. iPadOS also introduces new capabilities and intuitive features that take advantage of the unique characteristics of iPad. For more information, visit apple.com/ios/ios-13-preview and apple.com/ipados/ipados-preview. Features are subject to change. Some features may not be available in all regions or all languages.

1 The new Siri voice, personalization features on HomePod and Voice Control are available in English only.

2 QuickPath is not available in all languages.

Apple revolutionized personal technology with the introduction of the Macintosh in 1984. Today, Apple leads the world in innovation with iPhone, iPad, Mac, Apple Watch and Apple TV. Apple’s four software platforms — iOS, macOS, watchOS and tvOS — provide seamless experiences across all Apple devices and empower people with breakthrough services including the App Store, Apple Music, Apple Pay and iCloud. Apple’s more than 100,000 employees are dedicated to making the best products on earth, and to leaving the world better than we found it.

NOTE TO EDITORS: For additional information visit Apple Newsroom (www.apple.com/newsroom), or call Apple’s Media Helpline at [phone].

© 2019 Apple Inc. All rights reserved. Apple, the Apple logo, iPhone, Face ID, Touch ID, Memoji, Animoji, Siri, CarPlay, HomePod, Handoff, AirPods, SiriKit, iPad, Mac, iCloud Drive, App Store, iPadOS, iPad Air, iPad Pro and iPad mini are trademarks of Apple Inc. Other company and product names may be trademarks of their respective owners.


View source version on businesswire.com: https://www.businesswire.com/news/home/20190603005711/en/

Apple
Jacqueline Roy, [phone]
[e-mail]
Nadine Haija, [phone]
[e-mail]

[$Pistol Pete$]

Happy Father’s Day!!!!

I want to congratulate all the men out there who are working diligently to be good fathers whether they are stepfathers, or biological fathers or just spiritual fathers.

[$Pistol Pete$]

$S U.S. Justice Department set to decide on T-Mobile, Sprint merger as soon as next week - source

[mick]

$CBBT-Short Selling Data
Short Interest
47,236
(674700%)
05/15/2019
Significant Failures to Deliver
No

[mick]

American Lithium Expands TLC Project to 4,000 Acres and Demonstrates Mineral Processing Recovery to 90% in Ten Minutes
VANCOUVER, British Columbia, July 11, 2019 — American Lithium Corp. (“ALC” or “the Company”) (LI.V) (LIACF) (5LA1.F) a leading acquisition, exploration and development operator is extremely pleased to provide an update on its promising TLC sedimentary lithium project located just 12 kilometers from the regional mining centre of Tonopah, Nevada.

Highlights

Drilling

Core samples from 5 drill holes confirm stratigraphic and extension of mineralized lithium horizon over 6 square kilometers. An additional 5 reverse circulation drill holes have been permitted and the Company is waiting for drill rig availability to drill these holes. Assay results for the core holes are pending.
Processing

2nd phase leach testing returned exceptional results indicating a 90% Lithium extraction in 10 minutes with a fifty percent (50%) reduction in reagent consumption. The results confirmed continuous process capability for lithium recovery at scale. The Company therefore believes processing scalability will not limit the scope or size of a proposed mining operation.
Permitting

The Company has strategically expanded its acreage position to 1650 ha or 4,000 acres in 200 lode claims.
Resource Study

Company has engaged renowned sediment hosted lithium expert, Jerry Aiken, to produce a maiden lithium resource estimate.
Preliminary mineralogy indicates dominance of lepidolite. Mass balance suggests significant free lithium in addition to the lithium present in the lepidolite.

[mick]

THIS WEEK: The Trump administration is conducting asylum hearings in makeshift tent facilities by the ports of entry in Laredo and Brownsville for migrants who have been forced to wait months in Mexico under the chaotic Migrant Protection Protocols program. Members of the press are normally allowed to observe immigration court proceedings—but the Trump administration is blocking journalists and members of the public from attending the hearings.